Daljeet Kohli Has A Winner In JB Chem. Don’t Miss His Other Pharma Stock Recommendations

When I noticed that Ashish Kacholia had recently grabbed a huge chunk of JB Chem, I knew that the sun would shine on the stock sooner or later. Ashish Kacholia’s portfolio of glittering multi-baggers tells you that this savvy investor doesn’t touch a stock if he is not convinced that there are hefty gains in store for him. I sounded the alert (Why Is Ashish Kacholia Interested In JB Chemicals?) and also grabbed a chunk of the stock for myself.

Of course, credit for discovering JB Chemicals as the stock to bet on goes to Daljeet Kohli. He had recommended a buy in October 2013 when the stock was at Rs. 94. When things got a bit rough and investors got rattled, Daljeet’s soothing voice of comfort gave them the confidence to hold on and increase their positions (see Grab This Chance To Buy JB Chem Stock: Daljeet Kohli).

At today’s CMP of Rs. 178, JB Chem has given a return of 89% since Daljeet’s first recommendation about 8 months ago. The YOY return is a fabulous 125%.

Another stock that has been on fire since Daljeet put a buy on it is Sharon Bio-Medicine. I covered it in my piece “Is Sharon Bio-Medicine Going To Be A Multi-Bagger Like Ajanta Pharma & Alembic?” In just the few weeks since then, the stock has given a splendid return of 26% and looks like it has a lot of steam left in it.

Anyway, now the important point is that Daljeet Kohli has released a report in which he has analyzed the prospects of the top Pharma companies and given clear cut advice about the stocks that you should buy or hold. Alembic Pharma, Cadila, JB Chemicals, Shilpa Medicare etc have been given the coveted status of ‘Buy’ while Ajanta Pharma and others have been put on ‘Hold’.

Following Daljeet’s advice, I grabbed a chunk of Shipla Medicare (I already have a chunk from earlier). Shilpa is also backed by savvy investors like Baring Equity and Tano Capital and it should not come as a surprise if it delivers out-sized gains in the foreseeable future.